Chembio Diagnostics Announces Closing of Public Offering of Common Stock

Rhea-AI Summary

Chembio Diagnostics (CEMI) closed its public offering of 2,619,593 shares at $11.75 per share, generating approximately $30.8 million in gross proceeds. The offering included an additional 281,125 shares as part of the underwriters' option. The funds will support a strategic refocus on manufacturing and commercializing the DPP COVID-19 System, expanding the sales force, and increasing manufacturing capacity. This offering is conducted under an effective shelf registration statement with the SEC.

Positive

• Raised approximately $30.8 million to bolster business strategy.
• Funds will enhance manufacturing and commercialization of the DPP COVID-19 System.
• Expansion of sales force to drive growth.

Negative

• None.

HAUPPAUGE, N.Y., May 11, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI) (“Chembio”), a leading point-of-care diagnostic company focused on infectious diseases, announced today the closing of its previously announced public offering of 2,619,593 shares of its common stock, which included 281,125 shares issued pursuant to the partial exercise by the underwriters of their option to purchase additional shares, at a public offering price of $11.75 per share for gross proceeds of approximately $30.8 million. All shares of common stock sold in the offering were offered by Chembio.

Chembio intends to use the net proceeds from the offering to support the refocus of its business strategy, including the manufacturing and further commercialization of the DPP COVID‑19 System, to expand its sales force to support growth, to increase its manufacturing capacity, and for other general corporate purposes.

Baird acted as sole book-running manager for the offering. Dougherty & Company LLC acted as co‑manager for the offering.

The offering was made pursuant to an effective shelf registration statement on Form S-3 (No. 333-227398) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and a prospectus supplement and accompanying prospectus, which are available on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained by contacting Robert W. Baird & Co. Incorporated, Attention: Syndicate Department, 777 E. Wisconsin Avenue, Milwaukee, WI 53202, by telephone at (800) 792-2473 or by email at syndicate@rwbaird.com. 

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases including COVID-19, sexually transmitted disease and fever and tropical disease. Chembio’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.

DPP is Chembio’s registered trademark. For convenience, this trademark appears in this release without ^® symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to its trademark.

Forward-Looking Statements
This press release contains statements concerning, among other matters, the anticipated use of net proceeds from the offering, that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management’s current views based on certain assumptions, and they involve risks and uncertainties. Actual results, events or performance may differ materially from the forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including risks described in public reports filed by Chembio with the SEC, including under the caption “Risk Factors” in Chembio’s Annual Report on Form 10‑K for the fiscal year ended December 31, 2019, as amended, and Chembio’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. Chembio undertakes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Contact:  
Philip Taylor
Gilmartin Group
(415) 937-5406
investor@chembio.com

FAQ

What is the total amount raised by Chembio Diagnostics in its recent stock offering?

Chembio Diagnostics raised approximately $30.8 million in its recent stock offering.

How many shares were offered in Chembio Diagnostics' public offering?

Chembio Diagnostics offered a total of 2,619,593 shares in its public offering.

What will Chembio Diagnostics use the proceeds from the stock offering for?

Chembio Diagnostics intends to use the proceeds to support the DPP COVID-19 System, expand its sales force, and increase manufacturing capacity.

What was the offering price per share for Chembio Diagnostics' recent stock offering?

The offering price per share for Chembio Diagnostics' recent stock offering was $11.75.

Which firm acted as the book-running manager for Chembio Diagnostics' stock offering?

Baird acted as the sole book-running manager for Chembio Diagnostics' stock offering.